It turns out that AI really is doing the work. At least a growing chunk of it. Artificial intelligence is spreading through the global workforce like wildfire, dwarfing the adoption pace of the internet, with a new Anthropic report citing Gallup research that 40% of U.S. employees now use AI at work. While the field…
IQVIA’s AI vision is to cut pharmacovigilance costs by 50% with superhuman accuracy
![[Adobe Stock]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/11/AdobeStock_844651123-copy-268x170.webp)
Pharmaceutical companies could slash their pharmacovigilance costs by half while significantly improving accuracy through generative AI, according to IQVIA’s Global Practice Lead of Pharmacovigilance Technologies, Uwe Trinks. “The idea is: we can save 50% of the cost and get the quality to above 99%,” Trinks said. “That means when we have human verification, we only…
Natalizumab and PML: The complex dance of benefit and risk for MS
Biogen’s Tysabri (natalizumab), the first humanized monoclonal antibody for multiple sclerosis (MS), sparked optimism among MS patients following its FDA approval in 2004. The drug offered significant benefits, reducing relapses for patients resistant to other treatments. This was a significant milestone in the treatment of MS, but the journey of natalizumab and PML soon took…